Clinical cancer research 2002: New agents and therapies

Drug Resistance Updates

Volumn 5, Issue 5, 2002, Pages 192-203

  Gietema, J A ^a   De Vries, E G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Angiogenesis inhibitors; Epidermal growth factor receptor antagonists

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CANERTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TAMOXIFEN; TIPIFARNIB; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VASCULOTROPIN; VINBLASTINE; ENZYME INHIBITOR;

ACNE; ACUTE KIDNEY FAILURE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PAIN; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CARCINOMA; CLINICAL STUDY; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CORRELATION ANALYSIS; DIARRHEA; DRUG ACCUMULATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FOLLOW UP; GASTROENTERITIS; GERM CELL TUMOR; HEAD AND NECK CANCER; HUMAN; HYPERCALCEMIA; INFECTION; LEUKOPENIA; LONG TERM CARE; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LYMPH NODE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; RADIATION RESPONSE; RANDOMIZATION; RASH; REVIEW; SKIN ALLERGY; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOPHLEBITIS; VOMITING; ANIMAL; BIOSYNTHESIS; CONFERENCE PAPER; DRUG ANTAGONISM; MEDICAL RESEARCH; METHODOLOGY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); STATISTICS;

ANIMALS; BIOMEDICAL RESEARCH; CLINICAL TRIALS; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0036814435     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368764602001061     Document Type: Review

References (50)

1. Adjei, A.A., Mauer, A., Marks, R., Hillman, S., Bruzek, L.M., Geyer, S., Hanson, L.J., Erlichman, C., Kaufmann, S.H., Vokes, E.E., 2002. A phase II study of the farnesyltransferase inhibitor R115777 in patients with advanced non-small cell lung cancer. Proc. ASCO 21 (1156), 290a.
2. Alberts, D.S., Liu, P.Y., Hannigan, E.V., O'Toole, R., Williams, S.D., Young, J.A., Franklin, E.W., Clarke-Pearson, D.L., Malviya, V.K., DuBeshter, B., 1996. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. New Engl. J. Med. 335, 1950-1955.
3. Armstrong, D.K., Bundy, B.N., Baergen, R., Lele, S.B., Copeland, L.J., Walker, J., Burger, R., 2002. Randomized phase III study of intravenous (i.v.) paclitaxel and cisplatin versus i.v. paclitaxel, intraperitoneal (i.p.) cisplatin and i.p. paclitaxel in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial (GOG 172). Proc. ASCO 21 (803), 201a.
4. Baselga, J., Trigo, J.M., Bourhis, J., Tortochaux, J., Cortes-Funes, H., Hitt, R., Gascon, P., Muesser, M., Harstrick, A., Eckardt, A., 2002. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen. Proc. ASCO 21 (900), 226a.
5. Brahmer, J.R., Kelsey, S., Scigalla, P., Hill, G., Bello, C., Elza-Brown, K., Donehower, R., Kimmel, S., 2002. A phase I study of SU6668 in patients with refractory solid tumors. Proc. ASCO 21 (335), 84a.
6. Burtness, B.A., Li, Y., Flood, W., Mattar, B.I., Forastiere, A.A., 2002. Phase III trial HNC comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head & neck cancer (HNC). Proc. ASCO 21 (901), 226a.
7. Cohen, E.E., Rosen, F., Dekker, A., Bajda, C., Stenson, K., Shulman, K.L., Lamont, E., Kozloff, M., Vokes, E.E., 2002. Phase II study of ZD1839 (Iressa) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Proc. ASCO 21 (899), 225a.
8. Crown, J.P., Lind, M., Gould, A., Verrill, M., Twelves, C., Coleman, R., Perren, T., Van Belle, S., Wilson, C., Ledermann, J., Barrett-Lee, P.J., Heart, D., Kennedy, I., Simmons, P., Mansi, J.L., Jones, A., Cameron, D., Poole, C., Foster, L., Leonard, R., 2002. High-dose chemotherapy (HDC) with autograft (PBP) support is not superior to cyclophosphamide (CPA), methotrexate and 5-FU (CMF) following doxorubicin (D) induction in patients (pts) with breast cancer (BC) and 4 or more involved axillary lymph nodes (4+LN): The Anglo-Celtic I study. Proc. ASCO 21 (166), 42a.
9. Cunningham, D., de Gramont, A., Scheithauer, W., Smakal, M., Humblet, Y., Kurteva, G., Iveson, T., Andre, T., Dostalova, J., Illes, A., Jia, X., Palmer, P., 2002. Randomized double-blind placebo-controlled trial of the farnesyltransferase inhibitor R115777 (Zarnestra™) in advanced refractory colorectal cancer. Proc. ASCO 21 (502), 126a.
10. Dahut, W.L., Arlen, P.M., Gulley, J., Parker, C., Fedenko, K., Noone, M., Hamilton, M., Chen, C., Jones, E., Linehan, M., Pluda, J., Figg, W.D., 2002. A randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. Proc. ASCO 21 (730), 183a.
11. De Vos, F.Y., Hoekstra, R., Gietema, J.A., Eskens, F.A., Van der Gaast, A., Carr, R., Glad-Anderson, S., Humerickhouse, R., Groen, H.J., de Vries, E.G.E., Verweij, J., 2002. A phase I dose escalating study of the angiogenesis inhibitor thrombospondin-mimetic (ABT-510) in patients with advanced cancer. Proc. ASCO 21 (324), 82a.
12. Dicker, A.P., Anne, R., Bonanni, R., Sidor, C., Gubish, E., Curran Jr., W.J., 2002. Phase I trial results of recombinant human angiostatin protein (rhA) and external beam radiation therapy (EBRT). Proc. ASCO 2 (23), 17a.
13. Drucker, B.J., Schwartz, L., Marion, S., Motzer, R., 2002. Phase II trial of ZD1839 (Iressa), an EGF receptor inhibitor, in patients with advanced renal cell carcinoma. Proc. ASCO 21 (720), 181a.
14. Dumez, H., Hoekstra, R., Eskens, F., Sizer, K., Vaidyanathan, S., Ravera, C., van Oosterom, A., Verweij, J., 2002. A phase I and pharmacological study of PKI166, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally 3 times a week to patients with advanced cancer. Proc. ASCO 21 (341), 86a.
15. Eder, J.P., Clark, J., Supko, J., Garcia-Carboreo, R., Ryan, D.P., Shulman, L., Proper, J., Kirvan, M., Rattner, B., Connors, S., Keogan, M., Janicek, M., Kinchla, N., Fogler, W.E., Xu, G.X., Puchalski, T., Park, S., Schnipper, L., Phillips, E., Gubish, E., Sidor, C., Folkman, J., Soker, S., Kufe, D., 2002. A phase I trial of recombinant human endostatin. Proc. ASCO 21 (323), 81a.
16. Fan, M., Chambers, T.C., 2001. Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist. Updates 4, 253-267.
17. Forouzesh, B., Hidalgo, M., Takimoto, C., de Bono, J.S., Forero, L., Beeram, M., Malik, S., Patnaik, A., Rizzo, J., Hammond, L.A., Schwartz, G., Goetz, A., Mays, T., Kiene, A., Norris, J., Tolcher, A., Rowinsky, E.K., Nadler, P., Wood, D., Zitelli, A., 2002. Phase I pharmacokinetic (PK) and biological studies of the epidermal growth factor-tyrosine kinase (EGFR-TK) inhibitor OSI-774 in combination with docetaxel. Proc. ASCO 21 (81), 21a.
18. Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.Y., Nishiwaki, Y., Vansteenkiste, J.F., Kudo, S., Averbuch, S., Macleod, A., Feyereislova, A., Baselga, J., 2002. Final results from a phase II trial of ZD1839 (Iressa) for patients with advanced non-small-cell lung cancer IDEAL 1. Proc. ASCO 21 (1188), 298a.
19. Giantonio, B.J., Levy, D., Catalano, P.J., O'Dwyer, P.J., Benson III, A.B., 2002. Incorporating angiogenesis inhibition with bevacizumab (anti-VEGF) into frontline chemotherapy with irinotecan (CPT-11), fluorouracil and leucovorin (FU/LV) for advanced colorectal cancer (advCRC): A toxicity analysis of ECOG study E2200. Proc. ASCO 21 (503), 126a.
20. Goldberg, R.M., Morton, R.F., Sargent, D.J., Fuchs, C.S., Ramanathan, R.K., Williamson, S.K., Findlay, B.P., 2002. N9741: Oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI intergroup study. Proc. ASCO 21 (511), 128a.
21. Grasselli, G., Baselga, J., Sessa, C., Vigano, L., Locatelli, A., Trigo, J., Llado, A., Scigalla, P., Kelsey, S., Colombini, S., Marsoni, S., Gianni, L., 2002. Dose-escalation and pharmacologic study of oral SU-6668 in patients with advanced solid tumors. Proc. ASCO 21 (67), 18a.
22. Hoekman, K., Kuenen, B., Levi, M., Meijers, J., Giaccone, G., Van Hinsbergh, V., Pinedo, H., 2002. Activation of the coagulation cascade and endothelial cell perturbation during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. Proc. ASCO 21 (21), 6a.
23. Hoekstra, R., Dumez, H., Van Oosterom, A.T., Sizer, K.C., Ravera, C., Vaidyanathan, S., Verweij, J., Eskens, F.A., 2002. A phase I and pharmacological study of PKI166, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally in a two weeks on, two weeks off scheme to patients with advanced cancer. Proc. ASCO 21 (340), 86a.
24. Joly, F., Mangioni, C., Nicoletto, M., Manikhas, G.M., Walker, J., Mietlowski, W., Jones, G., Wysowskyj, H., Dugan, M., 2002. A phase 3 study of PSC 833 in combination with paclitaxel and carboplatin (PC-PSC) versus paclitaxel and carboplatin (PC) alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary cancer of the peritoneum. Proc. ASCO 21 (806), 202a.
25. Kies, M.S., Arquette, M.A., Nabell, L., Quinn, D., Shin, D., Needle, M.N., Waksal, H., Hong, W.K., Herbst, R.S., 2002. Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc. ASCO 21 (925), 232a.
26. Kris, M.G., Natale, R.B., Herbst, R.S., Lynch Jr., T.J., Prager, C., Belani, C.P., Schiller, J.H., Kelly, K., Spiridonidis, C., Albain, K.S., Brahmer, J.R., Sandler, A., Crawford, J., Lutzker, S.G., Lilenbaum, R., Helms, L., Wolf, M., Averbuch, S., Ochs, J., Kay, A., 2002. A phase II trial of ZD1839 (Iressa) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc. ASCO 21 (1166), 292a.
27. Kuenen, B.C., Rosen, L., Smit, E.F., 2002. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine and SU 5416 in patients with solid tumors, gemcitabine and SU 5416 in patients with solid tumors. J. Clin. Oncol. 20, 1657-1667.
28. Langmuir, V.K., Cobleigh, M.A., Herbst, R.S., Holmgren, E., Hurwitz, H., Kabbinavar, F., Miller, K., Novotny, W., 2002. Successful long-term therapy with bevacizumab (avastin) in solid tumors. Proc. ASCO 21 (32), 9a.
29. Lichtner, R.B., Schmidt, M., 2002. Perspectives of EGF receptor targeting in therapy resistant human tumors. Drug Resist. Updates 5, 11-18.
30. LoRusso, P.M., Adjei, A.A., Meyer, M.B., Wozniak, A., Gadgeel, S.M., Hanson, L.J., Reid, J.M., Mitchell, D.Y., Bruzek, L.M., Leopold, J.S., Herrera, R., Van Becelaere, K., Carlson, T., Packard, C., Gulyas, S.W., Erlichman, C., 2002. A phase 1 clinical and pharmacokinetic evaluation of the oral MEK inhibitor, CI-1040, administered for 21 consecutive days, repeated every 4 weeks in patients with advanced cancer. Proc. ASCO 21 (321), 81a.
31. Margolin, K., Gordon, M.S., Holmgren, E., 2001. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. J. Clin. Oncol. 19, 851-856.
32. Markman, M., Bundy, B.N., Alberts, D.S., Fowler, J.M., Clark-Pearson, D.L., Carson, L.F., Wadler, S., Sickel, J., 2001. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19, 1001-1007.
33. Mitchell, D.Y., Reid, J.M., Parchment, R.E., Meyer, M.B., Leopold, J.S., Herrera, R., Piens, J.R., Bruzek, L.M., Hanson, L.J., Van Becelaere, K., Carlson, T., Packard, C., Adjei, A.A., LoRusso, P.M., 2002. Pharmacokinetics (PK) and pharmacodynamics (PD) of the oral MEK inhibitor, CI-1040, following multiple dose administration to patients with advanced cancer. Proc. ASCO 21 (320), 81a.
34. Murren, J.R., Papadimitrakopoulou, V.A., Sizer, K.C., Vaidyanathan, S., Ravera, C., Abbruzzese, J.L., 2002. A phase I dose-escalating study to evaluate the biological activity and pharmacokinetics of PKI166, a novel tyrosine kinase inhibitor in patients with advanced cancers. Proc. ASCO 21 (377), 95a.
35. Olson, S.C., Baker, L., Cunningham, C.C., Garrison, M.A., Shin, D., Nemunaitis, J., Shin, H.J., Tolcher, A., Zinner, R., Eiseman, I., Lenehan, P., 2002. A population pharmacokinetic (PPK) analysis of oral CI-1033 a pan-erbB tyrosine kinase inhibitor, in patients with advanced solid tumors. Proc. ASCO 21 (361), 91a.
36. Prendergast, G.C., Du, W., 1999. Targeting farnesyltransferase: Is RAS relevant? Drug Resist. Updates 2, 81-84.
37. Rinehart, J.J., Wilding, G., Willson, J., Krishnamurthi, S., Natale, R., Mani, S., Burnett, C., Olson, S., Bycott, P., Owens-Grillo, J.K., Hes, M., Lenehan, P., 2002. A phase 1 clinical and pharmacokinetic study of oral CI-1033 a pan-erbB tyrosine kinase inhibitor in patients with advanced solid tumors. Proc. ASCO 21 (41), 11a.
38. Rosenberg, A.H., Loehrer, P.J., Needle, M.N., Waksal, H., Hollywood, E., Ramos, L., Saltz, L.B., 2002. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc. ASCO 21 (536), 135a.
39. Rosti, G., Pico, J.L., Wandt, H., Koza, V., Salvioni, R., Theodore, C., Lelli, G., Siegert, W., Horwich, A., Marangolo, M., Schmoll, H.J., Linkesch, W., Pizzocaro, G., Bouzy, J., Kramar, A., Droz, J.P., Biron, P., 2002. High-dose chemotherapy (HDC) in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors (GCT); first results of a prospective randomised trial of the European Group for Blood and Marrow Transplantation (EBMT): IT-94 study. Proc. ASCO 21 (716), 180a.
40. Rothenberg, M.L., Liu, P.Y., Wilczynski, S., Braly, P.S., Wadler, S., Stuart, G., Hannigan, E.V., Bonebrake, A.J., Alberts, D.S., Markman, M., 2002. Excellent 2-year survival in women with optimally-debulked ovarian cancer treated with intraperitoneal and intravenous chemotherapy: A SWOG-ECOG-NCIC study (S9619). Proc. ASCO 21 (809), 203a.
41. Saltz, L.B., Cox, J.V., Blanke, C., Rosen, L.S., Fehrenbacher, L., Moore, M.J., Maroun, J.A., Ackland, S.P., Locker, P.K., Pirotta, N., Elfring, G.L., Miller, L.L., 2000. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer Irinotecan Study Group. New Engl. J. Med. 343, 905-914.
42. Saltz, L., Meropol, N.J., Loehrer, P.J., Waksal, H., Needle, M.N., Mayer, R.J., 2002. Single agent IMC-C225 (Erbitux™) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc. ASCO 21 (504), 127a.
43. Saltz, L., Rubin, M., Hochster, H., 2001. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc. ASCO 20 (7), 3a.
44. Verweij, J., de Vries, E.G.E., 2001. Clinical cancer research 2001: New agents and therapies. Drug Resist. Updates 4, 217-223.
45. Voest, E.E., Beerepoot, L.V., Groenewegen, G., Fogler, W.E., Lee Sim, B.K., Sidor, C., Phillips, E., Zonnenberg, B.A., Schramel, F., Gebbink, M.F., Witteveen, P.O., 2002. Phase I trial of recombinant human angiostatin by twice-daily subcutaneous injection in patients with advanced cancer. Proc. ASCO 21 (322), 81a.
46. Willemse, P.H., De Vos, F.Y., Bos, A.M., de Vries, E.G.E., Van der Zee, A.G., Beijnen, J.H., Rosing, H., Mourits, M.J., Hospers, G.A., 2002. Intraperitoneal topotecan with standard carboplatin and paclitaxel in ovarian cancer is feasible. Proc. ASCO 21, 2350.
47. Winquist, E., Nabid, A., Sicheri, D., Ganguly, P., Venkatesan, V., Schneider, K., MacKinnon, J., Laurie, S., 2002. A phase I dose escalation study of a humanized monoclonal antibody to EGFR (hR3) in patients with locally advanced squamous cell cancer of the head and neck (SCCHN) treated with radiotherapy (RT). Proc. ASCO 21 (926), 232a.
48. Yang, J.C., Haworth, L., Steinberg, S.M., Rosenberg, S.A., Novotny, W., 2002. A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer. Proc. ASCO 21 (15), 4a.
49. Zander, A.R., Krüger, W., Kröger, N., Schmoor, C., Möbus, V., Frickhofen, N., Metzner, B., Schultze, W., Berdel, W.E., Königsmann, M., Wandt, H., Possinger, K., Trümper, L., Pflügler, K., Schumacher, M., Jonat, W., 1658. High-dose chemotherapy with autolgous hematopoietic stem-cell support (HSCS) vs. standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: First results of a randomized trial. Proc. ASCO 21, 415a.
50. Zinner, R.G., Donato, N.J., Nemunaitis, J.J., Cunningham, C.C., Shin, H.J., Zentgraf, R.E., Ayers, G.D., Glisson, B.S., Khuri, F.R., Kies, M.S., Eiseman, I., Lenehan, P.F., Hong, W.K., Shin, D.M., 2002. Biomarker modulation in tumor and skin biopsy samples from patients with solid tumors following treatment with the pan-erbB tyrosine kinase inhibitor CI-1033. Proc. ASCO 21 (58), 15a.